- Investor's Business Daily•1 hour ago
Broadcom and Finisar got price-target hikes after beating earnings estimates late Thursday, while Astrazeneca got an upgrade.
- Reuters•5 hours ago
AstraZeneca's immunotherapy drug durvalumab, the British drugmaker's most important pipeline medicine, has been accepted for review by U.S. regulators against bladder cancer, potentially its first use. ...
- Investopedia•7 hours ago
Falling revenues from its best-selling drugs have led to severe cost-cutting measures.
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||27.13 x 600|
|Ask||27.21 x 700|
|Day's Range||26.70 - 27.42|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.87|
|Dividend & Yield||0.90 (3.43%)|
|1y Target Est||N/A|